News - OxyDial Inc

Aug 14 2025

Agios Pharmaceuticals Achieves Landmark Approval for PYRUKYND® in Thalassemia in Saudi Arabia

Agios Pharmaceuticals has made history with the first-ever regulatory approval of PYRUKYND® (mitapivat) for thalassemia, granted by Saudi Arabia’s SFDA – هيئة الغذاء والدواء under its Breakthrough Medicines Program. This …

OxyDial

Aug 7 2025

Novo Nordisk Partners With ASH to Strengthen Sickle Cell Disease Care Across Sub-Saharan Africa

NovoNordisk has launched a strategic three-year partnership with the American Society of Hematology (@ASHSociety) to enhance sickle cell disease (SCD) care in sub-Saharan Africa. The collaboration will strengthen the Consortium …

OxyDial

Jul 31 2025

Functional Fluidics Collaborates With Safi Biotherapeutics to Advance Manufactured Red Blood Cells for Sickle Cell Disease

Functional Fluidics has partnered with Safi Biotherapeutics Inc to validate the quality and efficacy of Safi’s stem-cell-derived manufactured red blood cells (mRBCs) for sickle cell disease (SCD). This collaboration aims …

OxyDial

Jul 24 2025

Pfizer’s Inclacumab Study Advances as a Potential Breakthrough for Sickle Cell Disease

Pfizer has shared an update on its open-label extension study evaluating the long-term safety of inclacumab in individuals with sickle cell disease (SCD). This monoclonal antibody, administered intravenously every 12 …

OxyDial

Jul 17 2025

NIH Partners with Vascarta Inc. to Launch Phase 1 Trial of Non-Opioid Pain Gel VAS-101 for Sickle Cell Disease

The NIH/NHLBI/HEMATOLOGY BRANCH have signed an agreement with Vascarta, Inc to conduct a Phase 1 clinical trial of VAS-101 (Vasceptor®), a topical curcumin gel designed to reduce pain and inflammation …

OxyDial

Jul 10 2025

Bristol-Myers Squibb’s ELEMENT-MDS Trial Advances: A New Horizon for Anemia Treatment in MDS

Bristol Myers Squibb has reached a critical milestone in its ELEMENT-MDS Phase 3 trial, evaluating luspatercept versus epoetin alfa for treating anemia in adults with lower-risk myelodysplastic syndromes (MDS) who …

OxyDial

Jul 4 2025

CLY-124 Enters Clinical Trials as First Oral Globin-Switching Therapy for Sickle Cell Disease

Cellarity has dosed the first participant in a Phase 1 trial for CLY-124, a groundbreaking oral therapy designed to treat sickle cell disease (SCD) by reactivating fetal hemoglobin (HbF) through …

OxyDial

Jun 26 2025

Osivelotor Shows Promise for Sickle Cell Disease in New Trial Data

New findings from the ongoing phase 2/3 trial of osivelotor (GBT021601) by Global Blood Therapeutics/Pfizer highlight its potential to improve red blood cell health in sickle cell patients. Presented at EHA …

OxyDial

Jun 19 2025

VAS-101 (Vasceptor) Gets Orphan Drug Status for Sickle Cell Disease – A Promising New Approach

Vascarta Inc.’s VAS-101 (Vasceptor), an innovative topical curcumin treatment, has just received Orphan Drug Designation from the FDA. This status could fast-track its development, offering hope for safer, more effective …